Holen Sie sich die Stockscreener-App
21.87
4.03%
0.7988
Schlusskurs vom Vortag:
$21.07
Offen:
$21.21
24-Stunden-Volumen:
1.38M
Relative Volume:
0.55
Marktkapitalisierung:
$2.77B
Einnahmen:
$642.82M
Nettoeinkommen (Verlust:
$-43.54M
KGV:
-62.55
EPS:
-0.3496
Netto-Cashflow:
$130.12M
1W Leistung:
-2.23%
1M Leistung:
-11.62%
6M Leistung:
+37.94%
1J Leistung:
+140.34%
1-Tages-Spanne:
$21.20
$22.52
1-Wochen-Bereich:
$19.82
$22.52
52-Wochen-Spanne:
$8.065
$26.45
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
21.84 | 2.67B | 642.82M | -43.54M | 130.12M | -0.3496 |
VEEV
Veeva Systems Inc
|
156.80 | 25.41B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
58.18 | 10.96B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
45.67 | 8.24B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
82.49 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
53.44 | 4.18B | 587.86M | -425.10M | 0 | -5.691 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results - simplywall.st
QUADRANT CAPITAL GROUP LLC's 10x Genomics Inc(TXG) Holding History - GuruFocus
10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property Review
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - Yahoo Finance
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - The Motley Fool
10x Genomics Q1 earnings call highlights - MSN
TXG News | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
10x Genomics Q1 Earnings Call Highlights - sharewise.com
MSN Money - MSN
10x, Curio Settle Genomics Patent Suit Before Trial - Law360
10x, Harvard Sue Sequencing Co. Over Biology Patents - Law360
Harvard, 10x Patent Suit Targets Newer Cell-Mapping Platform - Bloomberg Law News
Why 10x Genomics (TXG) Stock Is Down Today - TradingView
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up - TradingView
Deutsche Bank Adjusts 10x Genomics Price Target to $23 From $17, Maintains Hold Rating - Moomoo
TXG Financials: Income Statement, Balance Sheet & Cash Flow | 10X Genomics, Inc. - Stock Titan
BofA Securities Maintains 10x Genomics(TXG.US) With Hold Rating, Maintains Target Price $30 - Moomoo
10X GENOMICS ($TXG) Releases Q1 2026 Earnings - Moomoo
10x Genomics, Inc. (NASDAQ:TXG) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript : 10x Genomics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
10x Genomics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates - sharewise.com
10x Genomics (TXG) Q1 2026 Earnings Transcript - The Globe and Mail
10X Genomics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
10x Genomics (NASDAQ: TXG) boosts Q1 2026 margins on consumables growth - Stock Titan
10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year - ChartMill
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q1 Revenue $150.8M, vs. FactSet Est of $146.4M - marketscreener.com
10x Genomics (TXG) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
10x Genomics: Q1 Earnings Snapshot - KTVB
Q1 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q1 CY2026: Beats On Revenue But Stock Drops - Yahoo Finance
10x Genomics Reports First Quarter 2026 Financial Results - PR Newswire
10x Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Q1 2026: 10x Genomics (NASDAQ: TXG) narrows loss, launches Atera - Stock Titan
10X Genomics faces earnings test as AI promise meets funding reality By Investing.com - Investing.com Australia
10X Genomics faces earnings test as AI promise meets funding reality - Investing.com Nigeria
TXG Technical Analysis | Trend, Signals & Chart Patterns | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Should Launch of Atera Spatial Biology Platform Require Action From 10x Genomics (TXG) Investors? - Yahoo Finance
10x Genomics (TXG) price target increased by 12.41% to 23.75 - MSN
M&T Bank Corp Has $1.19 Million Stake in 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Mar 23 '26 |
Sale |
19.13 |
10,000 |
191,297 |
1,177,273 |
| Saxonov Serge | Chief Executive Officer |
Mar 24 '26 |
Sale |
19.52 |
5,000 |
97,612 |
1,172,273 |
| Saxonov Serge | Chief Executive Officer |
Mar 02 '26 |
Sale |
22.73 |
16,152 |
367,097 |
1,203,667 |
0.51%
22.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):